No worries Mirri. Agreed - the split would be helpful.
The common figure I see in literature is ~30% of CRT patients are non-responders, a notable portion of which is related to ineffective lead placement. Using the top-line figures in the prospectus, that's 29,100 patients or an addressable market of ~$1.0B US in the States alone. A huge opportunity that is out-of-scope for the time-being.
General Investor Information EBR Systems, page-177
Add EBR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
97.0¢ |
Change
-0.010(1.02%) |
Mkt cap ! $358.0M | |||
| Open | High | Low | Value | Volume |
| 99.0¢ | 99.5¢ | 96.0¢ | $170.4K | 175.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 12057 | 95.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 97.5¢ | 5000 | 1 |
View Market Depth
| Last trade - 15.57pm 19/11/2024 (20 minute delay) ? |
| EBR (ASX) Chart |